EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 FOXO TECHNOLOGIES INC.’S SUBSIDIARY VECTOR BIOSOURCE, INC. ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE FOUR BLOOD COLLECTION CENTERS FROM GRIFOLS BIO SUPPLIES, INC. WEST PALM BEACH, FL, July 29, 2026 (GLOBE NEWSWIRE) - FOXO Technologies Inc.’s (OTC: FOXOD/FOXO) ( “FOXO”) subsidiary, Vector BioSource, Inc. (“Vector”) today announced that it has entered into a definitive agreement to acquire four U.S.-based blood collection centers (the “Agreement”) from Grifols Bio Supplies, Inc., a U.S.-based subsidiary of Grifols S.A. The acquisition is intended to provide a proprietary source of bio-products to sell to Vector’s customers to augment its existing sourcing model. Furthermore, the new FDA licensure that Vector expects to be required is anticipated to further expand Vector’s accessible market. The Agreement, structured as a purchase of certain assets relating to four collection centers located in the United States, consists of an upfront payment in cash and a potential future earnout payment, payable if the acquired centers reach certain EBITDA targets (as defined in the Agreement) in any of calendar years 2026, 2027 or 2028. Based on h…
Open exhibit ↗Current Report · Items 7.01, 9.01 · 8-K
FOXO TECHNOLOGIES INC
Regulation FD Disclosure
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Description of Exhibit Number ────────────────────────────────────────────────────────────────────── 99.1 Press Release Dated July 29, 2026 104 Cover Page Interactive Data File (formatted in Inline XBRL)
Company context
We are a healthcare services and technology company operating in three reportable business segments: (i) Healthcare, (ii) Life Science Services and (iii) Labs, formerly referred to as Labs and Life. These segments further operate in four synergistic divisions, a rural hospital division and a mental and behavioral health division, which make up our Healthcare segment, a biospecimens division, which makes up our Life Science Services segment and an epigenetics diagnostics and interpretation division, which makes up our Labs segment. Our rural hospital division, biospecimens division and epigenetics diagnostics and interpretation division operate through wholly owned subsidiaries, and our behavioral health division operates through a majority-owned subsidiary.